Chief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL)
Nuvalent Inc (NASDAQ:NUVL), a company specializing in the development of precisely targeted therapies for patients with cancer, has reported an insider sale according to a recent SEC filing. Chief Development Officer Darlene Noci sold 20,000 shares of the company on March 22, 2024. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this SEC Filing link.Over the past year, the insider has sold a total of 124,000 shares of Nuvalent Inc (NASDAQ:NUVL) and has not made any purchases of the stock. The recent sale by the insider is part of a broader trend observed within the company, where there have been no insider buys but 35 insider sells over the past year.On the date of the reported sale, shares of Nuvalent Inc (NASDAQ:NUVL) were trading at $77.51. The company's market capitalization stood at $4.897 billion.
The insider transaction history suggests a pattern of sales by company insiders, which may be of interest to current and potential investors. It is important for investors to consider insider transactions as one of many factors when evaluating a company.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
